Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 619-370-5 | CAS number: 98725-11-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
- study according to OECD guideline 471, GLP, Salmonella typhimurium TA 1535, TA 1537, TA 1538 TA 98 and TA 100 strains exposed to 9.8, 20, 39, 78, 156, 312 µg Compimide 183/plate for 48 h, non-mutagenic
- study according to Abbreviated Japanese MOL/MHW/MITI Metaphase Analysis In CHO Cells In Vitro, similar to OECD guideline 473, Chinese hamster Ovary (CHO) were exposed to 2.5, 5, 10 and 20 µg MDAB/mL for 24h without metabolic activation and 6h with metabolic activation, clastogen
- study according to OECD guideline 471, GLP, Salmonella typhimurium and Escherichia coli strains were exposed to 1, 3, 10, 33, 100, 333, 1000, 3330 and 5000 µg MDAB/plate for 48 h, non-mutagenic, read-across
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- weight of evidence
- Study period:
- 1985-03-12 to 1985-04-05
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study with acceptable restrictions
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- 1981
- Deviations:
- no
- GLP compliance:
- not specified
- Type of assay:
- bacterial reverse mutation assay
- Species / strain / cell type:
- other: S. typhimurium TA 1535, TA 1537, TA 1538, TA 98 and TA 100
- Additional strain / cell type characteristics:
- not specified
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9 mix
- Test concentrations with justification for top dose:
- 9.8, 20, 39, 78, 156, 312 µ/plate, the test concentrations were chosen based on bacterial toxicity measured in a preliminary test
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: Dimethyl formamide (DMF)
- Justification for choice of solvent/vehicle: Compimide 183 has been shown to be stable in DMF for at least 24h. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- other: 2-Aminofluorene, Neutral red
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: not specified
DURATION
- Exposure duration: 2 days
NUMBER OF REPLICATIONS: 3 each in two independent experiments - Evaluation criteria:
- not specified
- Key result
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 1538
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Conclusions:
- In the present study conducted similar to OECD guideline 471, Compimide 183 was tested for mutagenicity in the S. typhimurium tester strains TA 1535, TA 1537, TA 1538, TA 98, TA 100 in the following concentrations: 312, 156, 78, 39, 20, 9.8 µg/plate with and without metabolic activation by S9-liver mix. These concentrations were chosen due to cytotoxicity at 312 µg/plate and above.
There was no increase of revertant colonies up to the highest concentration tested, thus, Compimide 183 is considered to be non-mutagenic.
Reference
Table 1: In vitro semi-quantitative assays for mutagenicity, using Salmonella typhimurium tester strains in the presence and absence of rat liver microsomes, first assay
Compound |
Amount µg/plate |
Microsomes |
Revertant colonies per plate (a) |
||||
|
|
|
TA 1535 |
TA 1537 |
TA 1538 |
TA 98 |
TA 100 |
Compimide 183 |
312 |
+ |
3b |
NR |
NR |
NR |
93b |
|
|
- |
NT |
NT |
NT |
NT |
NT |
|
156 |
+ |
11b |
1b |
18b |
25b |
160b |
|
|
- |
2b |
NR |
8b |
7b |
103b |
|
78 |
+ |
22b |
9b |
22b |
32b |
134 |
|
|
- |
8b |
4b |
15b |
25b |
128b |
|
39 |
+ |
22 |
9 |
29 |
30 |
146 |
|
|
- |
17b |
10b |
21 |
26b |
116 |
|
20 |
+ |
22 |
8 |
26 |
31 |
139 |
|
|
- |
21b |
9 |
21 |
22 |
114 |
|
9.8 |
+ |
NT |
NT |
NT |
NT |
NT |
|
|
- |
18 |
10 |
21 |
28 |
127 |
Cyclophosamide |
250 |
+ |
> 500 c |
NT |
NT |
NT |
NT |
|
|
- |
161 |
NT |
NT |
NT |
NT |
Neutral red |
25 |
+ |
NT |
> 500 c |
NT |
NT |
NT |
|
|
- |
NT |
26 |
NT |
NT |
NT |
2-Aminofluorene |
50 |
+ |
NT |
NT |
> 2000 c |
> 2000 c |
> 1000 c |
|
|
- |
NT |
NT |
373 |
366 |
164 |
Dimethyl formamide |
|
+ |
22 |
9 |
22 |
32 |
133 |
|
|
- |
20 |
11 |
20 |
26 |
127 |
a: Mean value of three replicate plates
b: reduced lawn
c: Visual estimate; checked by auto colony counter
NR: Not recorded due to antibacterial activity
NT: Not tested
> greater than
Table 2: In vitro semi-quantitative assays for mutagenicity, using Salmonella typhimurium tester strains in the presence and absence of rat liver microsomes, second assay
Compound |
Amount µg/plate |
Microsomes |
Revertant colonies per plate (a) |
||||
|
|
|
TA 1535 |
TA 1537 |
TA 1538 |
TA 98 |
TA 100 |
Compimide 183 |
312 |
+ |
NR |
NR |
9b |
NR |
144b |
|
|
- |
NT |
NT |
NT |
NT |
NT |
|
156 |
+ |
15b |
9b |
22b |
29b |
144 |
|
|
- |
NR |
NR |
10b |
17b |
131b |
|
78 |
+ |
17b |
10 |
29b |
35b |
128 |
|
|
- |
13b |
7b |
13b |
25b |
147 |
|
39 |
+ |
22 |
10 |
25 |
31 |
152 |
|
|
- |
17b |
11b |
20 |
26 |
152 |
|
20 |
+ |
20 |
12 |
24 |
33 |
170 |
|
|
- |
19b |
12 |
20 |
25 |
150 |
|
9.8 |
+ |
NT |
NT |
NT |
NT |
NT |
|
|
- |
19 |
9 |
19 |
28 |
105 |
Cyclophosamide |
250 |
+ |
> 500 c |
NT |
NT |
NT |
NT |
|
|
- |
101 |
NT |
NT |
NT |
NT |
Neutral red |
25 |
+ |
NT |
> 500 c |
NT |
NT |
NT |
|
|
- |
NT |
19 |
NT |
NT |
NT |
2-Aminofluorene |
50 |
+ |
NT |
NT |
> 2000 c |
> 2000 c |
> 1000 c |
|
|
- |
NT |
NT |
192 |
199 |
181 |
Dimethyl formamide |
|
+ |
19 |
13 |
25 |
34 |
147 |
|
|
- |
19 |
11 |
20 |
29 |
130 |
a: Mean value of three replicate plates
b: reduced lawn
c: Visual estimate; checked by auto colony counter
NR: Not recorded due to antibacterial activity
NT: Not tested
> greater than
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In a study conducted similar to OECD guideline 471, Compimide 183 was tested for mutagenicity in the s. typhimurium tester strains TA 1535, TA 1537, TA 1538, TA 98, TA 100 in the following concentrations: 312, 156, 78, 39, 20, 9.8 µg/plate with and without metabolic activation by S9-liver mix. These concentrations were chosen due to cytotoxicity at 312 µg/plate and above. There was no increase of revertant colonies up to the highest concentration tested, thus, Compimide 183 is considered to be non-mutagenic.
In a study conducted similar to OECD 473 CHO cells (1E+05 cells/mL) were treated with 2.5, 5.0, 10.0 and 20.0 µg/mL MDAB either 24h without metabolic activation or 6h with metabolic activation. MDAB produced significant, dose-related increases in the frequency of chromosome abberations both in the presence anbd in the absence of a liver enzyme metabolising system. The test item is therefore considered to be clastogenic to CHO cells in vitro.
In a study according to OECD guideline 471, GLP, Salmonella typhimurium and Escherichia coli strains were exposed to 1, 3, 10, 33, 100, 333, 1000, 3330 and 5000 µg MDAB/plate for 48 h, it was concluded that MDAB is not mutagenic in the Salmonella typhimurium reverse mutation assay and in the Escherichia coli reverse mutation assay.
Justification for classification or non-classification
According to Regulation (EC) No 1272/2008 (CLP) and the Globally Harmonized System for Classification and Labelling of Chemicals (GHS) MDAB and Compimide do not need to be classified as mutagenic, but based on the results of a test conducted similar to OECD guideline 473, Compimide 183 needs to be classified as clastogenic according to Regulation (EC) No 1272/2008 (CLP) and the Globally Harmonized System for Classification and Labelling of Chemicals (GHS).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
